| scholarly article | Q13442814 |
| P50 | author | Elke Schaeffeler | Q49497789 |
| P2093 | author name string | Matthias Schwab | |
| Ulrich Klotz | |||
| Gerhard Treiber | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Helicobacter pylori | Q180556 |
| patient | Q181600 | ||
| P304 | page(s) | 201-209 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori | |
| P478 | volume | 76 |
| Q33984210 | AJG series: molecular biology for clinicians |
| Q36344158 | CYP2C19 genotype and the PPIs--focus on rabeprazole |
| Q35831792 | CYP2C19 polymorphism and proton pump inhibitors |
| Q36613862 | Clinical application of pharmacogenetics in gastrointestinal diseases |
| Q34280685 | Clinical application of pharmacogenomics |
| Q38212210 | Culture-guided treatment approach for Helicobacter pylori infection: review of the literature |
| Q46654300 | Determinants of non-response in Helicobacter pylori eradication trials |
| Q43109156 | Drug-induced liver injury: is it somehow foreseeable? |
| Q43145386 | Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States |
| Q37409135 | Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians |
| Q35987201 | Efficacy of esomeprazole in treating acid-related diseases in Japanese populations |
| Q38219028 | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype |
| Q53665185 | Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. |
| Q41859970 | Genetic polymorphisms, drug metabolism and drug concentrations. |
| Q26771197 | High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment |
| Q44790817 | Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany |
| Q24622513 | New concepts of resistance in the treatment of Helicobacter pylori infections |
| Q37768159 | Optimal management of peptic ulcer disease in the elderly |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q41706384 | Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q44371256 | Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori |
| Q38155930 | Pharmacokinetic behavior presents drug therapy challenges |
| Q37235086 | Proton pump inhibitors: an update of their clinical use and pharmacokinetics |
| Q37030772 | Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? |
| Q55280841 | Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. |
| Q34774061 | Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures |
| Q36616851 | Quadruple therapy for eradication of Helicobacter pylori |
| Q54592157 | Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. |
| Q34233142 | Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions |
| Q37899929 | Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
| Q44805919 | Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? |
| Q44149312 | The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers |
| Q36840621 | The clinical role of genetic polymorphisms in drug-metabolizing enzymes |
| Q36545135 | The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis |
| Q37981892 | The role of pharmacogenetics in nonmalignant gastrointestinal diseases |
| Q46641558 | Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond |
| Q36979297 | Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics |
| Q28550427 | Where Failure Is Not an Option -Personalized Medicine in Astronauts |
| Q87197258 | [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice] |
Search more.